Dings Ruud P M, Yokoyama Yumi, Ramakrishnan Sundaram, Griffioen Arjan W, Mayo Kevin H
Departments of Biochemistry, University of Minnesota Health Sciences Center, Minneapolis, Minnesota 55455, USA.
Cancer Res. 2003 Jan 15;63(2):382-5.
Recently, we demonstrated that the designed peptide anginex displays potent antiangiogenic activity. The aim of the present study was to investigate anginex treatment as a single-agent therapy and to test its ability to improve conventional chemotherapy and antiangiogenesis therapy. In a human ovarian carcinoma mouse model, anginex inhibited tumor growth by 70%. When anginex was combined with a suboptimal dose of carboplatin, tumors regressed to an impalpable state. Anginex plus angiostatin worked synergistically to inhibit tumor growth. Assessment of microvessel density suggested that the antitumor activity of anginex is mediated by angiogenesis inhibition. In any of the experiments, no sign of anginex-induced toxicity was observed.
最近，我们证明了设计的肽anginex具有强大的抗血管生成活性。本研究的目的是研究将anginex作为单一药物疗法，并测试其改善传统化疗和抗血管生成疗法的能力。在人卵巢癌小鼠模型中，anginex抑制肿瘤生长达70%。当anginex与次优剂量的卡铂联合使用时，肿瘤消退至无法触及的状态。Anginex加血管抑素协同作用抑制肿瘤生长。微血管密度评估表明，anginex的抗肿瘤活性是由血管生成抑制介导的。在任何实验中，均未观察到anginex诱导毒性的迹象。
